[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Umeå University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":704},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,48,73,100,126,153,185,214,236,261,287,326,359,386,418,449,474,496,524,552,578,600,627,653,680],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633264","local-radiotherapy-for-urinary-bladder-cancer-in-patients-not-eligible-for-curative-treatment-100633264",false,"NCT07524426","Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment","Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment; a Prospective Randomized Phase III Trial.","LORUP","Inclusion Criteria:\n\n1. Oral and written consent\n2. Histologically confirmed MIBC with urothelial component\n3. Male or female participants ≥ 18 years old\n4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord.\n\nExclusion Criteria:\n\n1. Clinical Fragility Scale score ≥8\n2. Previous pelvic RT with significant overlap\n3. Visceral or bone metastases on CT scan\n4. Multiple (\\>3) lymph node metastases with a measurement of \\>2 cm on CT scan\n5. Planed for systemic treatment at the time of inclusion.\n6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.","ALL","18 Years",{"count":21,"type":22},248,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone.\n\nUsing modern radiotherapy techniques, including hypofractionation and image-guided treatment adaptation, the aim is to deliver a well-tolerated, time-efficient, and effective treatment strategy for these patients.\n\nThe trial collaborates with two ongoing exploratory biomarker studies collecting and analyzing potential biomarkers in urothelial bladder cancer. The hope is to provide biomarkers for prognosis and treatment response which is essential to ensure bladder cancer patients individualized treatment in the future, like those with breast and prostate cancer.",[28],"Bladder Cancer (BC)",[16,30,31,32,33,34],"Bladder cancer","local radiotherapy","adaptive radiotherapy","Patient Reported Outcomes","Overall survival","RECRUITING","2026-06-05",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":39},"2026-06-03",{"date":43,"type":22},"2034-06",{"name":45,"class":46},"Umeå University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100643802","heart-failure-and-postoperative-outcome-in-surgery---a-national-registry-study-100643802","NCT07634822","Heart Failure and Postoperative Outcome in Surgery - a National Registry Study","Incidence of Heart Failure and Its Association With Postoperative Mortality in Surgery - a National Registry Study","Inclusion Criteria:\n\n* ≥18 years of age who underwent surgery in Sweden between 1 Jan 2021-31 Dec 2024 and SPOR registered operation.\n\nExclusion Criteria:\n\n* ASA 6 (deceased patient, organ donation).\n* Cardiac surgery",{"count":56,"type":22},2200000,"1 Year","OBSERVATIONAL","The study is an exploratory study that aims to explore the incidence of heart failure in a national surgical cohort, and to compare postoperative mortality and morbidity in patients with and without heart failure. Furthermore, we want to investigate differences in the incidence of heart failure and its impact on postoperative morbidity and mortality in day surgery compared to inpatient surgery.",[61,62,63],"Heart Failure","Diastolic Heart Failure","Systolic Heart Failure","NOT_YET_RECRUITING","2026-06-02",{"date":38,"type":39},{"date":68,"type":22},"2026-08",{"date":70,"type":22},"2030-12",{"name":45,"class":46},2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100643833","evaluation-of-the-relationship-between-medication-eye-movements-and-autonomic-nervous-system-ans-functions-in-children-and-adolescents-with-adhd-100643833","NCT07634809","Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System (ANS) Functions in Children and Adolescents With ADHD","Evaluation of the Relationship Between Medication, Eye Movements, and Autonomic Nervous System Functions in Children and Adolescents With ADHD","POP-Eye\u002FANSA","Inclusion Criteria:\n\n* ages of 6 -17\n* diagnosis of ADHD and agreed to medication administration in accordance with the clinic's procedures.\n\nExclusion Criteria:\n\n* diagnoses of arrhythmia, cardiovascular disease, or current substance use\n* concurrent use of non-steroidal asthma medications or beta-blockers\n* the inability to complete study participation before the participant's 18th birthday.\n* severe motor impairments and visual impairments that prevent participation in eye-tracking measurements.\n* caffeine intake within 4 hours prior to HRV and eye-tracking measurements","6 Years","17 Years",{"count":84,"type":22},150,"An increasing number of children are being diagnosed with ADHD, and the demand for ADHD medication has been rising. Although ADHD medication is often effective, this is unfortunately not the case for all children and adolescents with ADHD; furthermore, the majority of those who use the medication experience side effects of some kind. There are currently no known factors that are clearly linked to whether ADHD medications will be effective or cause significant side effects. The healthcare system therefore has limited ability to provide recommendations on ADHD medication at the individual level, which means that most children and adolescents with ADHD try medication. Studies show that 35% of children aged 4-11 and 53% of 12-17-year-olds discontinue ADHD medication within a year. Perhaps these children and adolescents could have avoided fruitless treatment attempts if the healthcare system had been able to provide better recommendations regarding when ADHD medications are most likely to be effective and tolerable treatment options. This, combined with reports of rising mental health issues and an avalanche-like increase in demand for child and adolescent psychiatric services, makes it particularly urgent to develop methods for offering effective interventions to the right patients as specifically as possible.\n\nPrevious studies have not consistently identified factors (neither genetic nor other factors such as gender, age, symptom severity, symptom profile, or comorbidities) that are linked to the efficacy or side effects of ADHD medications.\n\nIn this project, we will investigate whether the efficacy and side effects of ADHD medications are linked to eye movements or activity within the autonomic nervous system. The autonomic nervous system is the part of our nervous system that is not under our conscious control. It controls many bodily functions such as pupil size, heart rate, blood pressure, and reactions to stress.\n\nEye and pupil movements are measures of where an individual's attention is directed and how activated the brain is. ADHD is a condition in which the individual has difficulty regulating attention and activity. Therefore, there may be reason to believe that eye movements could be significant in the treatment of ADHD, even though this has never been studied before. Nor has the connection between the autonomic nervous system and the effects of ADHD medications been studied previously, even though changes in heart rate and blood pressure are among the common side effects of ADHD medications.\n\nWe will invite children and adolescents who are about to begin ADHD medication. Before they start taking the medication, we will measure eye movements, pupil dilation, and the pupil's reaction to light using so-called eye-tracking technology. This is done by having the child or adolescent look at a screen and follow certain instructions while the pupil's movements are measured. We will also measure heart rate variability, i.e., how much the pulse varies, which can be done by continuously measuring the pulse for 10 minutes. We will investigate whether there is a correlation between the characteristics of these eye movement, pupil, and heart factors before medication begins and the extent to which the medication produces effect and side effects. We will also analyze how these factors are affected by the medication.\n\nThe advantage of these factors is that they can be measured without causing pain. Furthermore, they are objective because they measure time and distance and are therefore not dependent on anyone's personal perceptions, as is so often the case with the rating scales otherwise used in psychiatry.\n\nIf we can identify correlations between eye movements and activity in the autonomic nervous system and how ADHD medications affect children and adolescents with ADHD, there is a possibility that this could be used to provide better recommendations regarding ADHD medication. Many children could then be recommended other interventions first and avoid unnecessary and unpleasant drug treatments.",[87],"ADHD - Attention Deficit Disorder With Hyperactivity",[89,90,91,92,93],"Attention deficit hyperactivity disorder (ADHD)","eye movement","autonomic nervous system activity","medication effects","children and adolescents",{"date":38,"type":39},{"date":96,"type":39},"2026-04-10",{"date":98,"type":22},"2028-11",{"name":45,"class":46},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":47},"100642849","development-of-a-pain-rehabilitation-program-for-chronic-pain-after-sci-100642849","NCT07634796","Development of a Pain Rehabilitation Program for Chronic Pain After SCI","Feasibility of a New Digital Pain Rehabilitation Program for People With SCI","Inclusion Criteria:\n\n* two years since injury\n* Stable pain medication?\n\nExclusion Criteria:\n\n* severe cognitive impairment\n* Alcohol or drug abuse\n* does not understand Swedish",{"count":108,"type":22},32,[25],"Pain rehabilitation programs are essential for optimal treatment of chronic pain and are usually based on the biopsychosocial model. This is, however, not standard care for people with chronic pain after a spinal cord injury (SCI) due to a biomedical focused perspective of SCI and lack of adapted programs.\n\nThe aims of this feasibility study:\n\n1. Develop a new digital pain rehabilitation program, adapted for the needs of people living with an SCI.\n2. To investigate the feasibility and acceptability of a new digital pain rehabilitation program.",[112,113,114,115,116],"Spinal Cord Injuries","Chronic Pain","Neuropathic Pain","Interprofessional Team Collaboration","Pain Management",[118,119],"participatory design","feasibility study",{"date":38,"type":39},{"date":122,"type":22},"2026-10-01",{"date":124,"type":22},"2027-09",{"name":45,"class":46},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":47},"100282760","dysphagia-evaluation-after-stroke--effect-oral-neuromuscular-training-on-swallowing-dysfunction-100282760","NCT02960737","Dysphagia Evaluation After Stroke- Effect Oral Neuromuscular Training on Swallowing Dysfunction","Dysphagia Evaluation After Stroke - a Randomized Controlled Trial of Oral Neuromuscular Training on Swallowing Dysfunction (DESIRE)","DESIRE","Inclusion Criteria:\n\n* Persistent dysphagia 12(±3) weeks after STROKE.\n\nExclusion Criteria:\n\n* Stroke patients with neurologic or psychiatric disorders or other diseases\u002Fconditions that can affect swallowing function.\n* Unable to collaborate due to other serious diseases and\u002For to affected general condition.",{"count":135,"type":22},60,[25],"The aim of this study is to investigate the effect of a specific rehabilitation program with an oral device used in stroke patients with persistent oral-and pharyngeal dysphagia.",[139,140],"Dysphagia","Stroke",[139,140,142,143,144],"Intervention","Oral neuromuscular training","Randomized control trial","2026-05-04",{"date":147,"type":39},"2026-05-08",{"date":149,"type":39},"2022-12-01",{"date":151,"type":22},"2029-03",{"name":45,"class":46},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":18,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100476980","the-ehealth-diabetes-remission-trial-100476980","NCT05491005","The eHealth Diabetes Remission Trial","eHealth Diabetes Remission Trial (Swedish: Remission av Typ 2 Diabetes Med hjälp av eHälsa","eDIT","Inclusion Criteria:\n\n* Type 2 diabetes with duration 0-6 years\n* BMI 27 kg\u002Fm2 and higher\n* HbA1c 43 mmol\u002Fmol or higher (48 or higher if without diabetes medication)\n\nExclusion Criteria:\n\n* Insulin treatment\n* Weight loss more than 5 kg during the past 6 months\n* Diagnosed eating disorder\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1,73m2\n* Myocardial infarction last six months\n* Severe heart failure (NYHA class III)\n* Ongoing cancer\n* Pregnancy\n* Treatment with antipsychotic drugs",true,"20 Years","70 Years",{"count":165,"type":22},106,[25],"Overweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy control group with normal glucose tolerance is examined once but is not randomised and does not receive any intervention.",[169],"Diabetes Mellitus, Type 2",[171,172,173,174,175],"Diabetes Remission","Nutrition Therapy","Obesity","eHealth","Weight Loss","2026-04-29",{"date":178,"type":39},"2026-04-30",{"date":180,"type":39},"2022-08-31",{"date":182,"type":22},"2028-01-31",{"name":45,"class":46},3,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":47},"100636722","long-term-outcomes-after-cdi-fmt-versus-antibiotic-only-treatment-100636722","NCT07569380","Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment","Long-Term Outcomes After Clostridioides Difficile Infection (CDI): Comparative Follow-Up of FMT Versus Antibiotic-Only Treatments (LTO-CDI Cohort)","LTO-CDI","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Symptomatic, microbiologically verified index CDI from February 1 2016 to December 31 2024\n* Having received CDI treatment at Umeå University Hospital (antibiotic-only or FMT)\n\nExclusion Criteria:\n\n* Age below 18 years at follow-up\n* Index CDI diagnosis not meeting ESCMID case definition\n* Testing positive for another gastrointestinal pathogen (virus\u002Fbacteria) that is more plausible to explain the clinical picture at index CDI episode\n* Declines participation",{"count":194,"type":22},250,"The goal of this observational study is to learn about the long-term effects of fecal microbiota transplantation (FMT) compared with antibiotic-only treatment in adults who were treated for Clostridioides difficile infection (CDI) at Umeå University Hospital between 2016 and 2024. The main questions it aims to answer are:\n\n* Do patients treated with FMT maintain higher gut bacterial diversity up to 10 years after CDI compared with patients treated with antibiotics only?\n* Do donor gut bacteria introduced by FMT persist long-term in the recipient's gut?\n* Are there differences in gut metabolism, gut barrier function, and systemic inflammation between FMT-treated and antibiotic-only treated patients at long-term follow-up?\n* What are the long-term safety outcomes - including new diseases, hospitalizations, and mortality - in FMT-treated versus antibiotic-only treated patients?\n\nResearchers will compare patients who received FMT to patients who received antibiotics only to see if FMT leads to lasting differences in gut microbiota, metabolism, immune markers, and clinical outcomes.\n\nParticipants will:\n\n* Attend a single study visit at Umeå University Hospital\n* Provide samples of blood, stool, urine, and a nasal swab\n* Complete two quality-of-life questionnaires\n\nClinical data will be collected from medical records for all participants.",[197],"Clostridioides Difficile Infection",[199,200,201,202,203,204,205],"Clostridioides difficile infection","Fecal microbiota transplantation","Gut microbiota","Microbiome engraftment","Intestinal barrier","Antibiotic treatment","Observational study","2026-04-28",{"date":208,"type":39},"2026-05-06",{"date":210,"type":22},"2026-05-01",{"date":212,"type":22},"2031-05-01",{"name":45,"class":46},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":161,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":47},"100633840","five-digits-test---validation-of-a-neuropsychological-test-of-inhibition-for-patients-with-neuropsychiatric-conditions-100633840","NCT07531914","Five Digits Test - Validation of a Neuropsychological Test of Inhibition for Patients With Neuropsychiatric Conditions","Inclusion Criteria:\n\n* age 18 and above\n* Diagnosed with a ADHD or Autism, alternatively under examination these diagnoses\n\nExclusion Criteria:\n\n* Addiction of alcohol or other substances\n* Not speaker of Swedish to such extent that cannot read or comprehend the informed consent forms\n* On sedatives, such as sleep or pain medication\n* Not being able to participate in a neuropsychological examination, or to give informed consent",{"count":84,"type":22},"Neuropsychiatric conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and autism are characterized by specific deficits in cognitive functions. Thus, neuropsychological assessment is a critical part of the diagnostic process for these conditions. Inhibition is a specific function of interest during these examinations, since it is often affected in patients with ADHD and\u002For autism. The Five Digits Test (FDT) is a newly developed test measuring inhibition, without requirements of reading ability, and only limited requirements of language proficiency.\n\nThe aim of this study is to investigate the validity of the FDT in patients with neuropsychiatric conditions. The FDT will be validated using the following research questions:\n\n1. Is the FDT equivalent to the standard neuropsychological test of inhibition, the Color-Word Interference Test from the Delis-Kaplan Executive Function System in patients with neuropsychiatric conditions? (Convergent validity)\n2. Is the FDT consistent with self-assessment of inhibition and behavioral regulation in every day life using the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)? (Ecological validity)\n3. Are there differences in validity in the first two research questions due to language background or due to reading and writing difficulties?\n4. Are there differences between patients with neuropsychiatric conditions and healthy controls in the performance of the FDT?",[223,224],"Autism","ADHD",[226,224,223,227],"Neuropsychological Assessment","Inhibition","2026-04-13",{"date":230,"type":39},"2026-04-15",{"date":232,"type":39},"2026-01-21",{"date":234,"type":22},"2027-12",{"name":45,"class":46},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":161,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":244,"conditions":245,"keywords":251,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":47},"100502188","remote-neuropsychological-assessment-of-patients-with-neurological-disorders-and-injuries-100502188","NCT05819008","Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries","Inclusion Criteria:\n\n* age 18 and above\n* Diagnosed with a neurological disorder or injury, alternatively under medical examination for such a diagnosis\n* Owns and can handle a computer with internet connection\n\nExclusion Criteria:\n\n* Severe psychiatric disorder, such a schizophrenia, severe depression\n* Addiction of alcohol or other substances\n* Not speaker of Swedish\n* On sedatives, such as sleep or pain medication\n* Multiple neurological diagnoses\n* Not being able to participate in a neuropsychological examination, or to give informed consent",{"count":243,"type":22},350,"For the last decades, many aspects of human life have been altered by digital technology. For health care, this have opened a possibility for patients who have difficulties travelling a long distance to a hospital to meet with their health care providers over different digital platforms. With an increased digital literacy, and an aging population often living in the countryside, far from hospitals or other health care settings, an increasing need for digitalization of meetings between patients and health care personnel is inevitable.\n\nHowever, neuropsychological assessment is one sort of health care not possible to directly transfer into digital form. These evaluations are most often performed with well validated tests, only to be used in a paper-pencil form with a specially trained psychologist during physical meetings.\n\nThe aim of this project is to investigate whether a newly developed digital neuropsychological test battery can be used to perform remote assessments of cognitive function in patients with neurological injuries and impairments. To this date, there are no such test batteries available in the Swedish language.\n\nMindmore (www.mindmore.com) is a test system developed in Sweden, performing neuropsychological tests on a tablet, but still with the psychologist present in the room. This system is now evolving into offering the possibility for the patient to perform the test in their own home, using their own computer or tablet. The aim of the present research project is to validate this latter system (Mindmore Distance), using the following research questions:\n\n1. Are the tests in Mindmore Distance equivalent to traditional neuropsychological tests in patients with traumatic brain injury, stroke, multiple sclerosis, Parkinson's Disease, epilepsy, and brain tumor?\n2. Can the results from Mindmore Distance be transferred into neuropsychological profiles that can be used in diagnostics for specific patient groups?\n3. How do the patients experience undergoing a neuropsychological evaluation on their own compared to traditional neuropsychological assessment in a physical meeting with a psychologist?",[246,140,247,248,249,250],"Traumatic Brain Injury","Multiple Sclerosis","Parkinson Disease","Epilepsy","Brain Tumor",[252],"Neuropsychological assessment","2026-03-31",{"date":255,"type":39},"2026-04-01",{"date":257,"type":39},"2023-03-10",{"date":259,"type":22},"2027-12-31",{"name":45,"class":46},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100626382","heparin-binding-protein-and-lungedema-in-icu-patients-100626382","NCT07434908","Heparin-binding Protein and Lungedema in ICU Patients.","Heparin-binding Protein (HBP) and Lungedema in ICU Patients. Is There a Correlation Between HBP and Pulmonary Vascular Permeability? A Prospective Observational Study","Inclusion Criteria:\n\n* Patients \\>18 years\n* Monitored with a PiCCO system\n\nExclusion Criteria:\n\n• Patients transferred from another ICU",{"count":7,"type":22},"The goal of this single center observational cohort study is to investigate the relationship between physiological measures of lung oedema, and the biomarker Heparin-binding Protein (HBP).\n\nThe main questions it aims to answer are:\n\n* Does the concentration of HBP in plasma correlate with measures of lung vascular permeability and extravascular water in the lungs?\n* Does the concentration of HBP in plasma correlate with the patient's total accumulated fluid balance?\n\nResearchers will collect blood samples and gather information on lung vascular permeability and extravascular lung water in Intensive care patients who are provided with a hemodynamic surveillance system called PiCCO. The study will include 25 patients.",[271],"Lung Edema",[273,271,274,275,276,277,278],"Heparin-binding Protein","Vascular permeability","Vascular leak","respiratory failure","PiCCO","Transpulmonary Thermodilution Technique","2026-03-09",{"date":281,"type":39},"2026-03-10",{"date":283,"type":39},"2024-05-06",{"date":285,"type":22},"2026-07-01",{"name":45,"class":46},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":295,"maxAge":82,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100624308","blended-trauma-focused-cognitive-behavioral-therapy-with-compassion-100624308","NCT07407946","Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion","Blended (mHealth) Trauma-Focused Cognitive Behavioral Therapy With Compassion for Adolescents With Post-Traumatic Stress Disorder: Protocol for a Pilot Randomized Controlled Trial in Northern Sweden","b-TF-CBT-C","Inclusion Criteria:\n\n* Adolescents aged 12-17 years.\n* Meet DSM-5 criteria for post-traumatic stress disorder (PTSD) confirmed by diagnostic interview (MINI-KID).\n* Score ≥25 on the Child and Adolescent Trauma Screen (CATS-2) at baseline.\n* Receiving care within routine child and adolescent psychiatric services in participating regions.\n* Have a non-offending caregiver willing and able to participate in caregiver components of treatment.\n* Able to communicate in Swedish sufficiently to engage in treatment and assessments.\n* Provide informed assent\u002Fconsent, with caregiver consent according to age and regulations.\n\nExclusion Criteria:\n\n* Acute suicidality or risk requiring inpatient care.\n* Active psychotic disorder or severe dissociative symptoms that interfere with participation.\n* Autism spectrum disorder, severe eating disorder, or obsessive-compulsive disorder requiring primary specialized treatment.\n* Ongoing trauma exposure or unstable living conditions that would prevent safe participation.\n* Cognitive impairment or medical condition that precludes participation in psychotherapy or digital components.\n* Substance use disorder requiring treatment, or regular use of benzodiazepines (\\> once per week).\n* Concurrent trauma-focused psychotherapy or recent initiation\u002Fdiscontinuation of psychotropic medication (within the past 6 weeks), or planned medication changes during the study period.","12 Years",{"count":297,"type":22},40,[25],"Brief Summary\n\nThe goal of this clinical trial is to evaluate the feasibility and acceptability of a blended (mHealth) Trauma-Focused Cognitive Behavioral Therapy with Compassion (bTF-CBT-C) for adolescents with post-traumatic stress disorder (PTSD) in routine child and adolescent psychiatric services in northern Sweden. The main questions it aims to answer are:\n\n* Is bTF-CBT-C feasible to deliver in routine care, as indicated by recruitment, retention, adherence to sessions and app modules, data completeness, and adverse events?\n* Is bTF-CBT-C acceptable to adolescents, caregivers, and therapists, as indicated by satisfaction, therapeutic alliance, digital treatment evaluation, and qualitative interviews? Researchers will compare bTF-CBT-C to standard TF-CBT to explore whether the blended format shows similar or potentially improved patterns in clinical outcomes (e.g., PTSD symptoms, emotion regulation, and self-compassion) and to estimate variability needed to plan a future non-inferiority trial.\n\nParticipants will:\n\n* Complete eligibility screening and baseline assessments, including a diagnostic interview for PTSD.\n* Be randomized to either bTF-CBT-C or standard TF-CBT.\n* Receive trauma-focused treatment over time, with caregiver involvement in both groups.\n* In the bTF-CBT-C group, use a secure mobile app for stabilization modules and exercises, together with therapist-led video sessions and selected in-person meetings.\n* Complete assessments at baseline, after stabilization, post-treatment, and at 6-month follow-up, and provide feedback about their experiences (questionnaires and interviews).",[301],"Post-traumatic Stress Disorder (PTSD)",[303,304,305,306,307,308,309,310,311,312,313,314,315,316,317],"post-traumatic stress disorder (ptsd)","Adolescent","Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)","Blended psychotherapy","Digital mental health","mHealth intervention","Compassion-focused therapy","Self-compassion","Emotion regulation","Shame and self-criticism","Caregiver involvement","Child and adolescent psychiatry","Rural mental health","Telehealth","Pilot randomized controlled trial","2026-02-24",{"date":320,"type":39},"2026-02-27",{"date":322,"type":39},"2026-02-23",{"date":324,"type":22},"2029-12-31",{"name":45,"class":46},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":333,"minAge":162,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":47},"100625477","menopausal-impact-of-opportunistic-salpingectomy-for-ovarian-cancer-prevention-100625477","NCT07423143","Menopausal Impact of Opportunistic Salpingectomy for Ovarian Cancer Prevention","MISSION-O","Inclusion Criteria:\n\n* Having had hysterectomy for a benign indication\n* Less than 55 years at surgery\n* Was included in the ITT population of the HOPPSA register-based randomised controlled trial (R-RCT) of opportunistic salpingectomy\n* Informed consent\n\nExclusion Criteria:\n\n* Ongoing systemic hormonal treatment using sex steroids\n* Bilateral oophorectomy\n* Cancer treatment affecting ovarian function\n* Other treatments with major effects on ovarian function","FEMALE","65 Years",{"count":336,"type":22},2100,[25],"The goal of this clinical trial is to find out whether removing the fallopian tubes at the time of hysterectomy leads to an earlier menopause. The study includes women under 55 years of age who previously underwent hysterectomy as participants in the HOPPSA trial, where they were randomly assigned to either removal of the fallopian tubes or no removal.\n\nThe main question is:\n\n• Does removing the fallopian tubes at the time of hysterectomy lead to an earlier menopause? Researchers will compare women who had their fallopian tubes removed during hysterectomy with women who had hysterectomy alone to see whether menopause occurs earlier after tube removal. Age at menopause will be estimated by measuring follicle-stimulating hormone (FSH) in small blood samples collected on a paper card.\n\nParticipants will:\n\n* Collect 4-5 drops of blood using a finger prick\n* Place the drops on a paper card and mail it to the researchers\n* Complete an online questionnaire These steps will be done twice, one year apart.",[340,341],"Menopause","Opportunistic Salpingectomy",[343,344,345,346,347,348,349,350],"opportunistic salpingectomy","hysterectomy","nested trial","randomised controlled trial","RCT","follicle-stimulating hormone","self-sampling","dried blood spot cards","2026-02-19",{"date":353,"type":39},"2026-02-20",{"date":355,"type":22},"2026-03",{"date":357,"type":22},"2057-12",{"name":45,"class":46},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":333,"minAge":19,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100625736","iris-risk-based-imaging-after-breast-conserving-surgery-100625736","NCT07426510","IRIS: Risk-Based Imaging After Breast-Conserving Surgery","Individualized Riskbased Imaging Surveillance After Breast-conserving Surgery for Breast Cancer (IRIS)- a Multicenter Randomized Trial","IRIS","Inclusion Criteria:\n\n* Histologically confirmed primary breast cancer\n* Treated with breast-conserving surgery with curative intent\n* Completed primary treatment according to clinical guidelines\n* Classified as having increased risk of recurrence according to predefined study risk criteria (based on factors such as age, tumor subtype)\n* Eligible for imaging surveillance\n* Registered in participating national or regional breast cancer registry\n* Able to comply with study follow-up procedures\n\nExclusion Criteria:\n\n* Previous ipsilateral or contralateral invasive breast cancer within the last 5 years (except index cancer)\n* Bilateral mastectomy\n* Known metastatic breast cancer at time of enrollment\n* Contraindication to contrast agents or MRI (if applicable for assigned arm)\n* Ongoing pregnancy at time of randomization\n* Any condition that, in the investigator's judgment, prevents participation in imaging surveillance",{"count":368,"type":22},2300,[25],"Breast cancer follow-up after curative treatment is currently based on largely uniform imaging surveillance strategies, despite substantial variation in recurrence risk across patient subgroups. Early detection of recurrences improves prognosis, particularly when detected by imaging rather than symptoms, but the optimal surveillance approach remains uncertain. Mammographic sensitivity is lower in breast cancer survivors than in screening populations, and interval cancers occur more frequently, especially among younger patients, those with dense breasts, aggressive tumor subtypes, or without radiotherapy after breast-conserving surgery.\n\nThis multicenter, open-label, register-based randomized controlled trial evaluates risk-stratified imaging surveillance after breast-conserving surgery for breast cancer. The study investigates whether more sensitive imaging methods, compared with standard mammographic follow-up, lead to earlier detection of ipsilateral recurrences and contralateral second primary breast cancers in patients at increased risk of recurrence.\n\nThe primary endpoint is the number of interval ipsilateral recurrences and contralateral second primary breast cancers detected within five years from index diagnosis. Secondary endpoints include stage at detection, breast cancer-specific survival, overall survival, recall rate, biopsy rate, false positive findings, and health-related quality of life.",[372],"Breast Cancer",[374,375,376,377,378,379],"Breast cancer","Imaging surveillance","Recurrence detection","Risk-stratified follow-up","MRI breast","Register-based randomized trial","2026-02-16",{"date":322,"type":39},{"date":68,"type":22},{"date":384,"type":22},"2034-01",{"name":45,"class":46},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":417},"100625032","single-stapled-technique-for-colorectal-anastomosis-100625032","NCT07417358","Single-Stapled Technique for Colorectal Anastomosis","Single-Stapled Technique for Colorectal Anastomosis After Left-Sided Colectomy, Sigmoid Resection or Partial Mesorectal Excision: A Multicentre Prospective Observational Cohort Study","SST","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Planned (elective) left-sided colorectal resection with creation of a colorectal anastomosis, including: Left hemicolectomy, and\u002For Sigmoid resection, and\u002For Partial mesorectal excision (PME).\n* Benign or malignant indication.\n* Prospective cohort: Ability to provide written informed consent.\n* Retrospective cohort: Eligible patients operated during 2023-2025 at participating centers, identified through medical record review, meeting the same surgical inclusion criteria.\n\nExclusion Criteria:\n\n* Total mesorectal excision (TME) (e.g., low rectal cancer surgery requiring TME).\n* Non-left-sided colorectal resections (e.g., right-sided colectomy) or procedures outside the study-defined operations.\n* Surgery not involving a colorectal anastomosis (e.g., end colostomy\u002FHartmann's procedure without anastomosis).\n* Emergency\u002Furgent colorectal resection (non-elective surgery).\n* Prospective cohort: Inability to provide informed consent.",{"count":395,"type":22},500,"The goal of this observational multicenter study is to evaluate the safety and feasibility of a single-stapled technique (SST) for colorectal anastomosis and to explore whether this technique is associated with a reduced rate of anastomotic leakage compared with the conventional double-stapled technique (DST).\n\nThe study includes adult patients undergoing planned left-sided colorectal resection with colorectal anastomosis, including sigmoid resection, left hemicolectomy, or partial mesorectal excision (PME), for benign or malignant disease.\n\nThe main questions it aims to answer are:\n\nWhat is the rate of anastomotic leakage within 90 days after surgery in patients operated with the single-stapled technique?\n\nIs the single-stapled technique feasible and safe across different surgical approaches (open, laparoscopic, and robot-assisted surgery) in a multicenter setting?\n\nFurthermore, outcomes after single-stapled anastomosis will be compared with a retrospective cohort of patients operated with the conventional double-stapled technique to explore potential differences in anastomotic leakage rates and postoperative complications.\n\nParticipants will receive standard surgical care as determined by the treating surgical team. Patients included in the prospective part of the study will undergo colorectal anastomosis using the single-stapled technique as part of routine clinical practice. Data on perioperative variables, postoperative complications (including anastomotic leakage graded according to international consensus definitions), and follow-up outcomes will be collected prospectively using an electronic case report form (eCRF). A retrospective cohort from the same participating centers will be identified through medical record review using identical inclusion criteria.\n\nThe results of this study are intended to provide robust multicenter data on the safety and clinical outcomes of the single-stapled technique and to serve as the basis for planning a future randomized controlled multicenter trial.",[398,399,400,401],"Colorectal Cancer","Colorectal Anastomosis","Anastomotic Leakage","Diverticular Disease of Left Side of Colon",[403,404,405,406,407,408],"Single-stapled anastomosis","Colorectal anastomosis","Anastomotic leakage","Colorectal surgery","Left-sided colon resection","Partial mesorectal excision","2026-02-10",{"date":411,"type":39},"2026-02-18",{"date":413,"type":39},"2026-01-07",{"date":415,"type":22},"2029-06-30",{"name":45,"class":46},5,{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":435,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":448},"100569011","intervention-for-neurodevelopmental-support-in-preterm-infants-using-responsive-parenting-and-e-health-100569011","NCT06688695","Intervention for Neurodevelopmental Support in Preterm Infants Using Responsive Parenting and E-health","Intervention for Neurodevelopmental Support in Preterm Infants Using Responsive Parenting and E-health (INSPIRE)","INSPIRE","Inclusion Criteria:\n\n\\* Infant born before 32 GV, or with birth weight under 1500 gr.\n\nExclusion Criteria:\n\n* Parent(s) younger than 18 ya.\n* Chromosomal abnormalities, congenital syndromes that may affect the child's development.\n* Parents unable to understand Swedish.\n* Parents with severe mental illness or a physical medical condition requiring extensive inpatient care.\n* Families without a stable living situation, such as parental substance abuse, homelessness, or family living under threat of deportation from Sweden.\n* Families that have previously participated in the INSPIRE study or the INSPIRE pilot study.","0 Months","4 Months",{"count":429,"type":22},176,[25],"Research problem and specific questions More than 1000 very preterm infants (\\< 32 weeks) are born every year in Sweden. They are at high risk of neurodevelopmental disabilities and mental illness throughout the lifespan.\n\nThe overall purpose is to develop and evaluate a novel e-health intervention aimed at improving neurodevelopment (cognitive, motor, feeding, language, socio-emotional) of very preterm infants by supporting responsive parenting behaviours.\n\nThe primary research question is whether the intervention improves child neurodevelopment up to 2 years.\n\nFurther research questions relate to the emotional availability of parents and children, parental stress and overall experience as well as effects on health inequalities and gender effects.\n\nData and method Using a multi-professional approach, the study team have developed a post-discharge \"Intervention for Neurodevelopmental Support in Preterm Infants using Responsive parenting and E-health\" (INSPIRE). Parents of very preterm infants will be included in the program at hospital discharge and will receive the intervention in 18 sessions over a two year period.\n\nThe study team have assessed feasibility and refined the intervention in a pilot study including 9 families. This autumn, a randomized clinical trial will be performed to evaluate efficiency: Families will be randomized to the INSPIRE program or standard care. Follow-up and assessment of children (and parents) across a range of crucial domains will be performed up to at least 2 years of age.\n\nSocietal relevance and utilisation The project will be the first in the world to use a digital e-health solution with video interaction to deliver a post discharge parental support intervention to parents of very preterm infants. The project has great potential to reduce the risk of cognitive impairment, behavioral problems, mental illness and eating disorders in these high risk children, as well as improving mental health and well-being in the parents. Parents of preterm infants are involved as co-creators in developing and evaluating the program.\n\nPlan for project realization Currently, there is no similar post-discharge program available. Based on the results, the study team aim to implement a sustainable, nationwide, post-discharge e-health intervention program to improve health in very preterm-born children and their parents, which will also reduce health inequality by ensuring the availability of high-quality support to families living far away from highly specialized health care facilities",[433,434],"Premature Infant","Premature Babies",[436,437,438,439],"Early intervention","Responsive parenting","E-health","Prematurity","2026-01-27",{"date":442,"type":39},"2026-01-28",{"date":444,"type":39},"2024-11-20",{"date":446,"type":22},"2029-10",{"name":45,"class":46},7,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":457,"targetDuration":459,"studyType":58,"phases":4,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100621705","clostridioides-difficile-understanding-responses-and-treatment-effects-100621705","NCT07374094","Clostridioides Difficile: Understanding Responses and Treatment Effects","Studies of Treatment Effects, Host-Pathogen Responses, and Therapeutic Mechanisms in Clostridioides Difficile Infection","CURE-CDI","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Symptomatic, microbiologically verified Clostridioides difficile infection\n* Receiving inpatient or outpatient care at Umeå University Hospital\n* Able and willing to provide written informed consent\n* Willing to participate in protocol-driven follow-up for up to 5 years\n\nExclusion Criteria:\n\n* Age below 18 years\n* Inability to provide written informed consent",{"count":458,"type":22},200,"5 Years","The goal of this observational study is to learn how different treatments for Clostridioides difficile infection (CDI) work, and which biological mechanisms are involved in recovery. The study will compare standard antibiotic treatment and fecal microbiota transplantation (FMT).\n\nThe main questions it aims to answer are:\n\n* How do antibiotic treatment and FMT affect treatment outcome in CDI?\n* How does the gut microbiota change during and after treatment?\n* Which microbial and metabolic factors are associated with recovery or treatment failure?\n* How does treatment affect the intestinal barrier, immune response, and patient-reported quality of life?\n\nParticipants with CDI will receive treatment as part of routine clinical care, either antibiotics or FMT. Researchers will follow participants over time and collect biological samples to study treatment effects.\n\nParticipants will:\n\n* Provide stool samples during the acute infection and during follow-up\n* Have treatment outcomes assessed at 2 and 8 weeks\n* Be followed for up to 5 years to study long-term effects\n* Provide blood and urine samples during follow-up\n* Provide nasal samples to study potential microbiota changes at distant body sites\n* Complete questionnaires on symptoms and health-related quality of life\n* In a subgroup, undergo repeated sigmoid biopsies to study intestinal mucosal healing\n\nThe results are expected to increase understanding of how FMT and antibiotics lead to recovery in CDI and may support improved and more targeted future treatments.",[197],[199,463,200,201,202,464,465,203,466,204,205],"Recurrent Clostridioides difficile infection","Dysbiosis","Microbial metabolites","Immune response","2026-01-20",{"date":442,"type":39},{"date":470,"type":22},"2026-01-26",{"date":472,"type":22},"2045-12",{"name":45,"class":46},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":47},"100619607","vdj-recombination-of-the-b-cell-receptor-following-hematopoietic-stem-cell-transplantation-100619607","NCT07346820","VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation","VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation, an Observational Study","VReST","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Willing and able to participate in all parts of the study.\n* Signed written consent.\n* Patients with a plasma cell disease of lymphoma that qualify for autologous hematological stem cell transplantation determined by the attending physician OR Patients with a condition for which allogenic stem cell transplantation could be needed and qualify for haematological stem cell transplantation according to the attending physician OR Stem cell donor, donating to a study participant.\n\nExclusion Criteria:\n\n* Unable to give informed consent.\n* Not suitable for participation in the study according to the view of the attending physician.\n* Previous participation in this trial.",{"count":483,"type":22},65,"When a person undergoes a stem cell transplant-an important procedure used to treat serious blood diseases such as leukaemia, lymphoma, or myeloma-the entire immune system is affected. The transplant essentially \"resets\" the immune system, meaning that the patient loses much of the protection against infections that has been built up over a lifetime. After the transplant, the patient therefore needs to be revaccinated against several diseases, such as tetanus, diphtheria, polio, COVID-19, and pneumococcal disease.\n\nIn this study, we aim to investigate how B cells-the immune cells that produce antibodies-reconstitute after a stem cell transplant. We are particularly interested in a genetic process called VDJ recombination, through which each B cell develops a unique receptor that enables it to recognize and fight a specific virus or bacterium. This process is what makes our immune system so effective. But what happens to this diversity after the entire immune system has been restarted with new stem cells? Does the body regain the same ability to recognize pathogens? Are there differences between patients who receive their own stem cells (autologous transplantation) and those who receive stem cells from another person (allogeneic transplantation)?\n\nTo answer these questions, we will follow patients undergoing stem cell transplantation at Umeå University Hospital. We will collect blood samples before and after the transplantation and will assess whether-and how well-patients generate antibodies in response to the vaccines given after transplantation. Using flow cytometry and genetic analyses, we will examine both which B-cell populations are generated and what their genetic architecture looks like. The goal is to understand how the new immune system is rebuilt after transplantation and, ultimately, to help improve vaccination strategies and infection prevention for this vulnerable patient group",[486,487,488],"Stem Cell Transplantation, Hematopoietic","V(D)J Recombination","Receptors, Antigen, B-Cel",{"date":490,"type":39},"2026-01-16",{"date":492,"type":22},"2026-02-01",{"date":494,"type":22},"2036-12-31",{"name":45,"class":46},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":513,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":417},"100617269","preoptimisation-in-ventral-hernia-surgery-100617269","NCT07316426","Preoptimisation in Ventral Hernia Surgery","Preoptimisation in Ventral Hernia Surgery- a Randomised Trial","PreOpt","Inclusion Criteria:\n\n* Patients with a ventral hernia with a defect width of at least 4 cm.\n* Symptom burden related to the hernia sufficient to justify surgical intervention.\n* Age ≥ 18 years.\n\nExclusion Criteria:\n\n* Expected survival of less than three years.\n* Inability to comprehend oral and written information or to provide informed consent.\n* Acute complication of the hernia requiring emergency surgical intervention.\n* General condition characterised by severe limitations in physical functional capacity.",{"count":505,"type":22},130,[25],"The study is a multicentre, single-blinded, randomised controlled trial. Ventral hernia patients with an aperture width between four and eight centimetres are randomised to either participation in a multimodal preoptimisation programme, including interventions to increase physical activity, promote weight loss, and optimise the treatment of comorbidities, or to surgery without structured preoptimisation. The primary endpoint is complications at three months postoperatively. During surgery, biopsies of skin, muscle, and fascia will be collected, along with pre- and postoperative blood samples, to analyse the molecular effects of preoptimisation, particularly in relation to collagen metabolism.",[509,510,511,512],"Hernia","Hernia, Ventral","Hernia Incisional","Hernia, Umbilical",[514,515],"preoptimisation","prehabilitation","2025-12-18",{"date":518,"type":39},"2026-01-05",{"date":520,"type":39},"2025-09-22",{"date":522,"type":22},"2029-09-01",{"name":45,"class":46},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":47},"100612836","diabetes-intervention-involving-person-centred-nutritional-education-100612836","NCT07258758","Diabetes Intervention Involving Person-centred Nutritional Education","Diabetes Intervention Involving Person-centred Nutritional Education (DINE) - Exploring the Benefits and Challenges of a Person-centred Education on the Nordic Diet for Adults With Type 1 Diabetes.","DINE","Inclusion Criteria:\n\n* Type 1 Diabetes.\n* Diabetes duration for more than 12 months at screening.\n* Adults 18 years or older.\n* HbA1c more than 57mmol\u002Fmol.\n* Use of continuous glucose monitoring (CGM) sensor for more than three months at screening and during the study period.\n* Use of basal and bolus insulin regimen for more than three months at screening and during the study period.\n* Written Informed Consent.\n\nExclusion Criteria:\n\n* Women of childbearing potential: ongoing pregnancy or planned pregnancy during the study period.\n* Cognitive impairment or other disease that study physician find non-compatible with participation.\n* Planned change in glucose lowering treatment during study period (change of mealtime insulin analogue with same pharmacodynamic profile allowed).\n* Planned change of CGM sensor during the study.\n* Food allergies or intolerances that are incompatible with adhering to Nordic nutrition recommendations.\n* Current or planned treatment with corticosteroids during the study (other than for replacement therapy).",{"count":533,"type":22},54,[25],"The overall objective for this project is to evaluate the effects of a person-centred education intervention to promote a healthy, sustainable Nordic diet compared with the current practice of providing short dietary information on health outcomes of adults with Type 1 diabetes. The study will measure the intervention's impact on blood glucose levels, blood lipids, blood pressure, and adherence to a sustainable and healthy Nordic diet.\n\nThe main question the trial aims to answer is:\n\nDoes a person-centred nutritional education have an impact on glucose time in range for adults with Type 1 diabetes, compared with short dietary information?\n\nThe participants will:\n\n* Attend either a person-centred nutrition education (intervention) or receive short dietary information (control group).\n* Wear their sensor for continuous glucose monitoring (CGM) throughout the trial.\n* Visit the clinic for data collection (blood samples and clinical checks) at the start and end of the trial.\n* Keep a four-day food diary, fill out a food frequency questionnaire (FFQ) and estimate their food enjoyment at the start and end of the trial.",[537],"Diabetes Type 1",[539,540,541,542,543],"Nutritional education","Person-centred care","Nordic diet","Diabetes intervention","Type 1 Diabetes","2025-12-04",{"date":546,"type":39},"2025-12-12",{"date":548,"type":39},"2025-09-01",{"date":550,"type":22},"2027-06",{"name":45,"class":46},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":564,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":47},"100432739","rehabkompassen---a-patient-centered-digital-follow-up-tool-in-the-post-stroke-continuum-of-care-100432739","NCT04915027","Rehabkompassen® - a Patient-centered Digital Follow-up Tool in the Post-stroke Continuum of Care","Rehabkompassen® - a Novel Digital Tool for Facilitating Patient-tailored Rehabilitation in the Post-acute Continuum of Care After Stroke - A Multicenter Pragmatic Randomized Controlled Trial","Inclusion criteria are\n\n1. Adults aged 18 years or older.\n2. With a stroke diagnosis\n\nTime since stroke onset:\n\n3a) For the big RCT group, Individuals must be within the first 4 months after stroke, starting from Day 1 after the occurrence of the stroke.\n\n3b) For primary care group, Individuals 3 months after stroke\n\nExclusion criteria are\n\n1. Unable to answer the evaluation questions.\n2. Unable to see the Rehabkompassen®graph.\n3. Not using BankID, an e-identification tool commonly used in Sweden.",{"count":560,"type":22},1106,[25],"Stroke is a leading cause of disability and with a heavy burden for the society. Despite the demands from 'Socialstyrelsen' of improving post-acute care, an effective structured follow-up to promote a patient-tailored rehabilitation remains largely lacking in the current stroke care.\n\nThe overall aim of this study is to find a cost-effective solution to facilitate patient-tailored rehabilitation that improves daily and social activities and health-related quality of life for persons discharged from the acute care after stroke. We have recently developed a novel digital graphic tool, Rehabkompassen®, which based on patient-reported outcome measurements captures the patient's complex health status after stroke.\n\nHere, this tool will be used in a parallel, open-label, 2-arm prospective and multicenter pragmatic randomized controlled trial between 2022-2026. All participants (n = 1106) will be randomized according to permuted block design; and receive a usual care without (control group, n = 553) or with (intervention group, n = 553) Rehabkompassen®, within 3-month after stroke. The effectiveness of the tool on daily and social activities, quality of life and its health-economic effects will be compared at 12-month follow-up post stroke.\n\nWe hypothesize that the digital tool Rehabkompassen® will provide a patient-tailored rehabilitation that improves recovery, independence, and quality of life among people with stroke in a cost-effective way.",[140],[565,566,567,568,569,570],"Stroke rehabilitation","Patient-tailored rehabilitation","Improvement of daily and social activity","Quality of life","Health economy","Pragmatic randomized clinical trial","2025-07-03",{"date":573,"type":39},"2025-07-09",{"date":575,"type":39},"2020-08-26",{"date":234,"type":22},{"name":45,"class":46},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":333,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":47},"100595927","implementation-of-the-app-ttii-for-treatment-of-urgency-and-mixed-urinary-incontinence-100595927","NCT07038811","Implementation of the App Tät®II for Treatment of Urgency and Mixed Urinary Incontinence","Inclusion Criteria:\n\n* Female gender\n* Age ≥18 years\n* Symptoms of urgency urinary incontinence or mixed urinary incontinence\n* Medical evaluation and documentation of urinary incontinence by ordinary doctor\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Childbirth in the last 6 months\n* Painful urges\n* Difficulties emptying the bladder\n* Blood in urine\n* Need of further investigation concerning the urinary incontinence, according to the clinical doctor",{"count":135,"type":22},"This observational study aims to evaluate the implementation and use of the Tät®II app for the treatment of urgency and mixed urinary incontinence in women over the age of 18 after contact with ordinary healthcare, as well as its effectiveness. The study aims to answer the following question:\n\nIs treatment via the app effective and feasible after primary care?\n\nParticipants will use the app for 15 weeks to treat urgency and mixed urinary incontinence. They will answer online survey questions about their urinary incontinence before, after 15 weeks, and one year after treatment.",[587,588],"Urgency Incontinence","Mixed Incontinence, Urge and Stress",[590,591],"urinary incontinence","app treatment","2025-06-23",{"date":594,"type":39},"2025-06-26",{"date":596,"type":39},"2025-06-12",{"date":598,"type":22},"2027-06-01",{"name":45,"class":46},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":161,"sex":333,"minAge":608,"maxAge":19,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":610,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":47},"100578646","a-randomised-controlled-trial-on-the-networks-integrating-anxiety-and-metabolism-in-anorexia-nervosa-100578646","NCT06814002","A Randomised Controlled Trial on the Networks Integrating Anxiety and Metabolism in Anorexia Nervosa","Networks Integrating Anxiety and Metabolism in Human Anorexia Nervosa, A Randomised Controlled Trial on Physiological and Psychological Responses to Caloric and Non-Caloric Meals","NAMA","Inclusion criteria:\n\n* Female individuals\n* 13-18 years of age\n* Currently patients at the eating disorder clinic\n* Newly diagnosed with AN according to the Diagnostic and Statistical Manual of mental disorders 5th edition (DSM-5)\n* Treatment naïve\n\nHealthy control participants will be matched on age-, sex-, and education level with the AN-participants. The clinical diagnosis\u002Fdiagnoses for participants will be validated\u002Fruled out by the Structured Clinical Interview for DSM-5 (SCID-5). The presence of other exclusion criteria will also be further explored at the clinical visit.\n\nExclusion criteria:\n\n* Having one or several chronic medical conditions that may interfere with or hinder participation, or affect study outcomes.\n* Use of medications that affect hormone levels or eating behaviors.\n* Having one or several severe psychiatric disorders other than AN (e.g., schizophrenia, major depressive disorder, bipolar disorder).\n* Current drug abuse, pregnancy or potential pregnancy (for AN patients these conditions are excluded as a part of routine care. For healthy controls no objective testing will be performed).\n* High risk of refeeding syndrome or severe complications related to eating disorders.\n* Inability to comply with the nutritional program of the study.\n* Allergies to foods included in the provided meal content.\n* Cognitive impairments preventing comprehension of the study or the informed consent process.\n* Contraindications for MRI (e.g., pacemaker, prosthesis, claustrophobia), and\n* Fasting blood glucose above 6.0 mmol\u002Fl on the morning of the study, as this indicates either non compliance with overnight fasting or pre-diabetes\u002Fdiabetes..\n\nAdditional exclusion criterion for healthy controls: (1.) Having one or several eating disorders, current or past.\n\nParticipant inclusion in the study will be determined by a study clinician based on the outlined eligibility criteria. In cases of uncertainty, the principal investigator will make the final decision. Importantly, to maintain impartiality and avoid selective recruitment bias, enrolling clinicians will be masked to future treatment allocations, as randomization will occur at a later point in time.","13 Years",{"count":135,"type":22},[25],"Anorexia nervosa (AN) is known as the psychiatric disorder with the highest mortality rate as long-term calorie restriction causes medical complications and suicide risk. The ineffectiveness of pharmacological treatments increases interest in the etiopathogenesis of the disease. This study aims to examine the effects of caloric and non-caloric food intake on stress response, changes in brain network activity in AN patients and healthy volunteers, and examine whether these changes are related to caloric intake through neuroendocrine and psychological responses.\n\nThe study will include 30 female AN patients aged 13-18 who are newly diagnosed and have not received any treatment, and 30 healthy volunteers matched by age, sex, and education level. The patient group will be admitted to the clinic's open inpatient unit on the evening before the study to ensure they have fasted. A 12-hour fasting period starting from the day before the procedure will be mandatory.\n\nIn the morning, patients will undergo psychiatric assessments and scales. Psychometric measurements will be applied to determine the clinical characteristics of participants. Visual Analog Scale (VAS) will be applied. VAS is used to evaluate subjective states such as hunger, satiety, desire to eat, anxiety, fear of obesity, sadness, appetite, general mood, and motivation to participate in the study. Following this, the first resting-state functional magnetic resonance imaging (fMRI) scan will be performed for 8 minutes.\n\nSubsequently, participants will be randomised with 1:1 allocation ratio to consume one of two jellies prepared by a dietitian: one containing 400 calories and the other calorie-free. Participants will not be forced to consume the food.\n\nThe ingredients and preparation methods were chosen to make the appearance and taste of the foods similar. Participants will not know which type of food (caloric\u002Fnon-caloric) they are given. Participants who do not wish to consume the provided food will be excluded from the study. Participants will be told that the mixture they will be consuming will either be balanced in nutritional value and caloric, or harmless and calorie-free. They will be given fifteen minutes to consume the mixture, and the amount they consume will be recorded. Sixty minutes after the consumption of the mixture, participants will undergo a second fMRI scan to identify the neuronal network changes induced by this process. The same procedures will be applied to the healthy control group. Before and after imaging, blood samples will be collected from participants for biochemical analysis. Endocrine markers such as glucose, insulin, ghrelin, obestatin, PYY, leptin, and cortisol will be evaluated to assess hunger, satiety, and stress responses. Changes in these parameters will be used to evaluate participants' physiological responses to meals. A second meal will be offered three hours after the first meal, and the amount consumed will be recorded.\n\nFour subgroups will be analysed in the study: AN patients who received calories, AN patients who did not receive calories, healthy controls who received calories, and healthy controls who did not receive calories. Outcome data will be collected before and after meal intake and the outcomes will be compared between the four groups.\n\nThe study aims to investigate the physiological, psychological and behavioural responses to caloric and non-caloric meals, and to compare the responses in patients and non-patients. It is hypothesized that the stress response observed in AN patients is not solely related to food intake but that the calorie content of the ingested food will cause additional activation in biologically stress-related networks, with corresponding effects on experience. The hypothesis that the differences observed between patients and controls are due to biological differences in AN patients will be tested. This study aims to shed light on the etiopathogenesis of AN and contribute to the development of new strategies for the treatment and management of AN.",[613],"Anorexia Nervosa",[613,347,615,616,617,618],"fMRI","calorie intake","Psychometric measures","Neuroendocrine biomarkers","2025-05-05",{"date":621,"type":39},"2025-05-08",{"date":623,"type":39},"2025-02-15",{"date":625,"type":22},"2026-12-31",{"name":45,"class":46},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":637,"briefSummary":638,"conditions":639,"keywords":641,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":652},"100397970","proton-versus-photon-therapy-in-anal-squamous-cell-carcinoma-100397970","NCT04462042","Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma","Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma - Swedish Anal Carcinoma Study","SWANCA","Inclusion Criteria:\n\n1. The patient must be at least 18 years old\n2. Histologically confirmed, previously untreated squamous cell carcinoma (p16-positive or p16-negative) of the anal canal (ICD-O-3 C21), i.e. cancer of the perianal skin without connection to the anal canal are not included. The patients may have primary tumour, regional nodes, metastasis (TNM)-stage T2 (\\>4 cm) -4,N0-1c,M0 (UICC 8th edition).\n3. World Health Organisation\u002FEastern Cooperative Oncology Group (WHO\u002FECOG) performance status 0-1\n4. The patient must be able to understand the information about the treatment and give a written informed consent.\n\nExclusion Criteria:\n\n1. Patients with cancer of the perianal skin without involvement of the anal canal (ICD-O-3 C44.5) are not eligible.\n2. Patient judged to have any other treatment than radiotherapy with concomitant chemotherapy as the preferred treatment\n3. Concomitant or previous malignancies. Exceptions are, adequately treated basal cell carcinoma or squamous cell carcinoma of the skin or, other previous malignancy with a disease-free interval of at least 5 years.\n4. Two or more synchronous primary cancers in the pelvic region at time of diagnosis\n5. Previous radiotherapy, surgery or chemotherapy that may interfere with the planned treatment for the present disease, as judged by the investigator.\n6. Co-existing disease prejudicing survival (expected survival should be \\>2 years).\n7. Pregnancy or breast feeding\n8. When prosthetic materials (e.g. hip prostheses) are present close to the target volume it must be considered if this may introduce uncertainties in dose calculations that precludes especially, proton therapy.\n9. Patients with pacemaker\u002FICD are not eligible.",{"count":636,"type":22},100,[25],"Dosimetric studies suggest that radiotherapy with protons has a potential to reduce side effects compared to treatment with photons for patients with anal carcinoma (AC). There are so far no studies comparing these treatment techniques in a randomised setting. The aim of this study is to compare side effects following photon therapy versus proton therapy within the framework of a randomised controlled trial.",[640],"Anal Cancer Squamous Cell",[642,643],"proton beam therapy","side effects","2025-03-28",{"date":646,"type":39},"2025-04-03",{"date":648,"type":39},"2021-04-07",{"date":650,"type":22},"2031-03-28",{"name":45,"class":46},4,{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":4,"eligibilityCriteria":659,"healthyVolunteers":161,"sex":18,"minAge":660,"maxAge":661,"enrollmentInfo":662,"targetDuration":4,"studyType":23,"phases":664,"briefSummary":665,"conditions":666,"keywords":671,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":679,"locationsCount":47},"100581830","hypertension-and-cerebrovascular-hemodynamics-in-general-anaesthesia-100581830","NCT06855407","Hypertension and Cerebrovascular Hemodynamics in General Anaesthesia","The Effects of Induced Hypertension on Cerebrovascular Hemodynamics During General Anaesthesia","Inclusion Criteria:\n\n* ASA classification 1-3\n* BMI 18,5-29.9\n* MMSE \\> 23\n* Elective surgery planned.\n\nExclusion Criteria:\n\n\\- Pacemaker or other contraindications for MRI.","50 Years","80 Years",{"count":663,"type":22},30,[25],"During anesthesia, blood pressure-raising medications are often required to achieve an adequate blood pressure level. However, there is limited knowledge about what constitutes an adequate blood pressure to ensure sufficient blood flow to the brain. This project aims to map the relationship between blood pressure and brain blood flow using an MRI scanner. The results will contribute to a better understanding of this relationship and lead to improved management of brain blood flow during surgery on anesthetized patients.\n\nHow does the project work?\n\nDay 1 Before planned surgery, participants will meet with an anesthesiologist for information and assessment. An MRI scan of the brain will be conducted while participants are awake. The MRI examination has no side effects or risks. The space inside the MRI scanner is tight, especially around the head. If discomfort is experienced, the examination will be stopped immediately. The machine is noisy, so hearing protection will be provided, and communication with staff will be possible throughout the examination. The scan takes approximately 30 minutes, during which participants only need to lie still and relax.\n\nDay 2 After planned surgery, an anesthesiologist and an anesthesia nurse will transfer participants to the MRI scanner while still under anesthesia. Participants will not be woken up between surgery and the MRI scan; instead, transportation will occur while still anesthetized, following standard hospital procedures.\n\nParticipants will remain under the same anesthetic drugs as during the surgery. The same blood pressure-raising medication, norepinephrine, will be continuously used.\n\nNo additional drugs, beyond those necessary for normal anesthesia, will be administered before the MRI examination.\n\nThe entire project will take about 1.5 hours in addition to the surgery. If an arterial catheter (a blood pressure monitor via an artery in the wrist) is not already in place, one will be inserted while participants are asleep.\n\nBefore the MRI examination:\n\nBaseline examination - If any abnormalities are detected, the scan will be stopped, and follow-up by a doctor will occur.\n\nBlood pressure increase - Blood pressure will be raised by approximately 30% (equivalent to mild physical activity, such as jogging).\n\nFollow-up scan at the higher blood pressure level. Blood pressure returns to normal. All blood pressure levels will remain within clinically acceptable ranges for anesthetized patients and will be regulated with the same medication as used during the surgery.\n\nAfter the MRI:\n\nParticipants will be woken up in the anesthesia preparation room next to the MRI scanner.\n\nThe arterial catheter will be removed before awakening. Participants will be transported to the postoperative unit for monitoring. The surgeon responsible for care will determine the discharge time.\n\nPossible Risks and Side Effects of Participation\n\nTransporting an anesthetized patient for an MRI scan outside the operating room carries some risks. However, the hospital has established procedures for daily transportation of anesthetized patients and a structured division of responsibilities to manage unexpected situations. Monitoring will be conducted by an experienced anesthesiologist and anesthesia nurse throughout the procedure.\n\nRoutine monitoring includes blood pressure, heart rate, depth of anesthesia, and oxygen levels.\n\nNo long-term effects have been observed from MRI scans or short-term anesthesia for these examinations.\n\nMost complications related to general anesthesia occur during induction or awakening, and these risks exist regardless of study participation.\n\nStudy participation may slightly increase the risk of IV lines or breathing tubes becoming dislodged due to movement while anesthetized.\n\nA prolonged period under anesthesia may cause slight additional fatigue upon waking.\n\nTo ensure understanding of the information about this study, participants will take a simple cognitive test (5 minutes) before surgery.\n\nIf any unexpected complications arise during surgery, study participation will be discontinued. If the MRI scan reveals any abnormalities, referral to a neurologist or neurosurgeon for further evaluation will be provided.\n\nWhat Happens to Collected Data?\n\nThe project will collect health information from medical records and MRI scans. All data will be pseudonymized (coded) so that it cannot be linked to individual participants.\n\nThe key to decoding this information will be stored securely by the research nurse at the Neuro-Head-Neck Center (NHHC).\n\nOnly authorized research personnel will have access to the pseudonymized data. Information will be protected in accordance with the General Data Protection Regulation (GDPR).",[667,668,669,670],"Anesthesia","Cerebral Blood Flow","Regional Cerebral Oxygen Saturation","Blood Pressure",[672],"induced hypertension","2025-03-10",{"date":675,"type":39},"2025-03-13",{"date":677,"type":39},"2024-12-06",{"date":598,"type":22},{"name":45,"class":46},{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":23,"phases":689,"briefSummary":690,"conditions":691,"keywords":694,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":47},"100518656","blood-pressure-treatment-in-icu-patients-with-subarachniodal-haemorrhage-100518656","NCT06033378","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage.","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage. -Can Blood Pressure Be Used As a Surrogate Marker for Blood Flow","BFBP","Inclusion Criteria:\n\n* Coiled or clipped aneurysm\n* Suspected or confirmed vasospasm\n\nExclusion Criteria:\n\n* BMI \\>30\n* Pregnancy\n* Pacemaker or other MRI contraindications\n* Severe congestive heart failure (NYHA III-IV) or cardiac arrhythmia.\n* Severe respiratory failure or FiO2 \\>0.6\n* Severe kidney failure",{"count":663,"type":22},[25],"An MRI study to examine the relationship between blood pressure and cerebral blood flow in patients with subarachnoidal hemorrhage and suspect or verified vasospasm.",[670,692,693],"Subarachnoid Hemorrhage","Aneurysm Cerebral",[695,696,697],"magnetic resonance imaging","norepinephrine","blood flow",{"date":675,"type":39},{"date":700,"type":39},"2023-09-01",{"date":702,"type":22},"2028-09-01",{"name":45,"class":46},""]